Prolonged haematologic toxicity in CAR‐T‐cell therapy: A review

Abstract

Chimeric antigen receptor‐T‐cell (CAR‐T‐cell) therapy is a novel immunotherapy with encouraging results for treatment of relapsed/refractory haematologic malignancies. With increasing use, our understanding of immune‐mediated side effects such as cytokine release syndrome and neurotoxicity has improved; nevertheless, prolonged haematologic toxicity (PHT), with a high incidence rate, remains underrecognized. Owing to heterogeneity in populations, the CAR‐T cells used and diseases treated as well as differences in the definition of PHT, its rate, risk factors and management vary across studies. In this review, we provide a narrative of PHT occurring in patients following CAR‐T‐cell therapy; evidence of PHT treatment strategies is also presented, with the aim of contributing to systematic understanding of PHT.

Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology

“…Despite the efficacy of the therapy in certain hematological malignancies, several challenges persist, including issues related to persistence, drug resistance, immune evasion, and toxic reactions (4)(5)(6)(7). Additionally, CAR-T cells have limited effectiveness in treating solid tumors.…”